Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMVTNASDAQ:PROKNASDAQ:RVMDNASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$15.47-2.1%$15.07$12.72▼$34.47$2.70B0.611.21 million shs1.07 million shsPROKProKidney$0.61-8.2%$0.81$0.46▼$2.59$193.21M1.36638,278 shs2.06 million shsRVMDRevolution Medicines$40.04+1.0%$39.47$29.17▼$62.40$7.39B1.11.54 million shs1.75 million shsRXRXRecursion Pharmaceuticals$4.83-4.0%$4.91$3.79▼$12.36$2.04B0.8415.38 million shs21.21 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant-2.09%-0.13%+6.98%-14.95%-43.37%PROKProKidney-8.20%-38.56%-14.72%-40.00%-75.76%RVMDRevolution Medicines+0.96%+0.68%+0.68%+4.14%+4.79%RXRXRecursion Pharmaceuticals-3.98%-3.40%+18.38%-26.03%-45.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMVTImmunovant1.3566 of 5 stars3.50.00.00.02.11.70.0PROKProKidney1.699 of 5 stars3.20.00.00.00.64.20.6RVMDRevolution Medicines4.3284 of 5 stars4.51.00.04.73.21.70.0RXRXRecursion Pharmaceuticals1.82 of 5 stars3.21.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMVTImmunovant 2.90Moderate Buy$38.33147.79% UpsidePROKProKidney 2.33Hold$4.50642.57% UpsideRVMDRevolution Medicines 3.00Buy$67.0867.54% UpsideRXRXRecursion Pharmaceuticals 2.33Hold$7.0044.93% UpsideCurrent Analyst Ratings BreakdownLatest RVMD, PROK, RXRX, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $5.005/14/2025RVMDRevolution MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $72.005/8/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.005/8/2025RVMDRevolution MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.005/8/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$87.00 ➝ $80.005/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.005/6/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.004/28/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.00 ➝ $67.004/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.004/10/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$10.00 ➝ $8.004/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.00 ➝ $59.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/APROKProKidney$80K2,217.20N/AN/A($3.41) per share-0.18RVMDRevolution Medicines$11.58M644.06N/AN/A$13.47 per share2.97RXRXRecursion Pharmaceuticals$58.84M33.37N/AN/A$2.61 per share1.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMVTImmunovant-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)PROKProKidney-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.00N/AN/AN/AN/A-37.06%-32.84%8/6/2025 (Estimated)RXRXRecursion Pharmaceuticals-$463.66M-$1.77N/AN/AN/A-961.32%-74.70%-54.02%8/6/2025 (Estimated)Latest RVMD, PROK, RXRX, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 million5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/A5/5/2025Q1 2025RXRXRecursion Pharmaceuticals-$0.44-$0.50-$0.06-$0.50$18.12 million$14.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMVTImmunovantN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMVTImmunovantN/A11.1611.16PROKProKidneyN/A10.9610.96RVMDRevolution MedicinesN/A13.4613.46RXRXRecursion Pharmaceuticals0.024.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMVTImmunovant47.08%PROKProKidney51.59%RVMDRevolution Medicines94.34%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipIMVTImmunovant5.90%PROKProKidney41.49%RVMDRevolution Medicines8.20%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMVTImmunovant120170.92 million160.84 millionOptionablePROKProKidney3292.70 million171.26 millionOptionableRVMDRevolution Medicines250186.27 million170.99 millionOptionableRXRXRecursion Pharmaceuticals400406.49 million372.23 millionOptionableRVMD, PROK, RXRX, and IMVT HeadlinesRecent News About These CompaniesRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Rating of "Hold" from AnalystsJune 24 at 2:41 AM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.1% - What's Next?June 23 at 2:56 PM | marketbeat.comRecursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for InvestorsJune 20, 2025 | zacks.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Position Boosted by SG Americas Securities LLCJune 20, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 5.6% - Here's What HappenedJune 19, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.5% - Time to Buy?June 18, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Given New $5.00 Price Target at Morgan StanleyJune 17, 2025 | americanbankingnews.comExpert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 AnalystsJune 17, 2025 | benzinga.comMorgan Stanley Lowers Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $5.00June 16, 2025 | marketbeat.comIs This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?June 16, 2025 | fool.comLeerink Partnrs Issues Positive Estimate for RXRX EarningsJune 15, 2025 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.2% - Here's WhyJune 13, 2025 | marketbeat.comLeerink Partnrs Has Positive Estimate for RXRX Q2 EarningsJune 13, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 2.4% - Should You Sell?June 12, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 4% Higher - Should You Buy?June 11, 2025 | marketbeat.comInsmed surges on lung drug data; Recursion cuts staffJune 11, 2025 | biopharmadive.comAI-Focused Recursion Pharmaceuticals Stock Jumped 31% Last Week; Here's Why June 11, 2025 | talkmarkets.comRecursion to lay off 20% of workforce amid biotech funding woesJune 11, 2025 | msn.comRecursion: Lack Of Near-Term Catalysts Leaves The Stock VulnerableJune 11, 2025 | seekingalpha.comRecursion lays off 20% of staff in wake of pipeline cutbacksJune 10, 2025 | fiercebiotech.comRecursion Pharmaceuticals Stock Is Up 10% Today: What's Happening?June 10, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRVMD, PROK, RXRX, and IMVT Company DescriptionsImmunovant NASDAQ:IMVT$15.47 -0.33 (-2.09%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$15.68 +0.21 (+1.35%) As of 04:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.ProKidney NASDAQ:PROK$0.61 -0.05 (-8.20%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$0.60 0.00 (-0.50%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Revolution Medicines NASDAQ:RVMD$40.04 +0.38 (+0.96%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$41.43 +1.39 (+3.47%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Recursion Pharmaceuticals NASDAQ:RXRX$4.83 -0.20 (-3.98%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$4.96 +0.14 (+2.80%) As of 05:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
